NCT06190730

Brief Summary

There are vulnerabilities in post-discharge care transition for patients after undergoing resection of malignant gastrointestinal tumors. This study aims to investigate the possibility of utilizing Voice-Assisted Remote Symptom Monitoring System (VARSMS) to alleviate some of these challenges.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
281

participants targeted

Target at P75+ for not_applicable

Timeline
20mo left

Started Jul 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress52%
Jul 2024Dec 2027

First Submitted

Initial submission to the registry

December 19, 2023

Completed
17 days until next milestone

First Posted

Study publicly available on registry

January 5, 2024

Completed
7 months until next milestone

Study Start

First participant enrolled

July 23, 2024

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2027

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

April 3, 2025

Status Verified

January 1, 2025

Enrollment Period

3.2 years

First QC Date

December 19, 2023

Last Update Submit

March 31, 2025

Conditions

Keywords

speech systemlarge language modelai

Outcome Measures

Primary Outcomes (1)

  • Custom questionnaire based on NCI PRO CTCAE (National Cancer Institute- Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events)

    Daily symptom-based self-reported assessment on dyspnea, fever, melena, pain, wound healing, activities of daily living, sensorium, gastrointestinal motility, dysphagia, pitting edema, mood, and an option to mention symptoms not asked of. This is monitored by the research team, and any concerning finding, at the discretion of the site's physician, will be relayed to the subject's treating physician. Treating physician has final decision on whether to address referral by adjustment of management.

    40 days

Secondary Outcomes (1)

  • SASSI (Subjective Assessment of Speech System Interfaces)

    40 days

Study Arms (2)

Control

NO INTERVENTION

Besides the consent process, subjects in this arm will have no other research-specific activities until after 40 days after the surgery for an exit interview.

Voice-Assisted Remote Symptom Monitoring System (VARSMS) group

EXPERIMENTAL

Subjects in this group will be issued the device, to be activated 1 day after discharge. The device will administer a set of questions daily.

Other: Voice-Assisted Remote Symptom Monitoring System (VARSMS)

Interventions

Utilizing an Alexa Skill activated via an Amazon Echo Dot device, this system will administer two patient-reported outcomes measures to subjects. This will not be used as basis for diagnosis, nor for any clinical intervention.

Also known as: Voice-Assisted Remote Symptom Monitoring System (VARSMS)- customization phase
Voice-Assisted Remote Symptom Monitoring System (VARSMS) group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • At least 18 years old. Ages of subjects \>89 will simply be reported as \>90.
  • Scheduled for a GI surgery for management of a tumor in a participating hospital.
  • Fluent in oral and written English.
  • Has consistent and continued full access to an operational Wi-Fi for the duration of the study.

You may not qualify if:

  • Unable to provide informed consent.
  • Not willing to commit to regular participation in the study to include daily use (40 days) of the study application.
  • Life expectancy of less than 60 days.
  • In the opinion of the investigator, participation in this study is contraindicated.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

MedStar Health

Baltimore, Maryland, 21218, United States

RECRUITING

Creighton University

Omaha, Nebraska, 68124, United States

RECRUITING

MeSH Terms

Conditions

Gastrointestinal NeoplasmsDigestive System Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: The Voice-Assisted Remote Symptom Monitoring System (VARSMS) will be installed on Amazon Echo Dot
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 19, 2023

First Posted

January 5, 2024

Study Start

July 23, 2024

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

April 3, 2025

Record last verified: 2025-01

Locations